المؤلفون: Girgis S; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA. SGirgis@its.jnj.com., Lin SXW; Janssen Research & Development, Spring House, PA, USA., Pillarisetti K; Janssen Research & Development, Spring House, PA, USA., Banerjee A; Janssen Research & Development, Spring House, PA, USA., Stephenson T; Janssen Research & Development, Spring House, PA, USA., Ma X; Janssen Research & Development, Spring House, PA, USA., Shetty S; Janssen Research & Development, Spring House, PA, USA., Yang TY; Janssen Research & Development, Spring House, PA, USA., Hilder BW; Janssen Research & Development, Spring House, PA, USA., Jiao Q; Janssen Research & Development, Spring House, PA, USA., Hanna B; Janssen Research & Development, Spring House, PA, USA., Adams HC 3rd; Janssen Research & Development, Spring House, PA, USA., Sun YN; Janssen Research & Development, Spring House, PA, USA., Sharma A; Janssen Research & Development, Tokyo, Japan., Smit J; Janssen Research & Development, Spring House, PA, USA., Infante JR; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA., Goldberg JD; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA., Elsayed Y; Janssen Research & Development, Spring House, PA, USA.

المصدر: Targeted oncology [Target Oncol] 2022 Sep; Vol. 17 (5), pp. 609.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Girgis S; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA. SGirgis@its.jnj.com., Lin SXW; Janssen Research & Development, Spring House, PA, USA., Pillarisetti K; Janssen Research & Development, Spring House, PA, USA., Banerjee A; Janssen Research & Development, Spring House, PA, USA., Stephenson T; Janssen Research & Development, Spring House, PA, USA., Ma X; Janssen Research & Development, Spring House, PA, USA., Shetty S; Janssen Research & Development, Spring House, PA, USA., Yang TY; Janssen Research & Development, Spring House, PA, USA., Hilder BW; Janssen Research & Development, Spring House, PA, USA., Jiao Q; Janssen Research & Development, Spring House, PA, USA., Hanna B; Janssen Research & Development, Spring House, PA, USA., Adams HC 3rd; Janssen Research & Development, Spring House, PA, USA., Sun YN; Janssen Research & Development, Spring House, PA, USA., Sharma A; Janssen Research & Development, Tokyo, Japan., Smit J; Janssen Research & Development, Spring House, PA, USA., Infante JR; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA., Goldberg JD; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA., Elsayed Y; Janssen Research & Development, Spring House, PA, USA.

المصدر: Targeted oncology [Target Oncol] 2022 Jul; Vol. 17 (4), pp. 433-439. Date of Electronic Publication: 2022 Jun 24.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Multiple Myeloma*/drug therapy, Administration, Intravenous ; B-Cell Maturation Antigen ; Humans

المؤلفون: Martens AWJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands., Rietveld JM; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Boer R; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Peters FS; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands., Ngo A; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Mil LWHG; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Heer K; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Flevoziekenhuis, Almere, the Netherlands., Spaargaren M; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Pathology, University of Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., Verkleij CPM; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Adams HC 3rd; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania., Eldering E; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., van Noesel CJM; Department of Pathology, University of Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., Verona R; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania., Kater AP; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands.

المصدر: Cancer research communications [Cancer Res Commun] 2022 May 09; Vol. 2 (5), pp. 330-341. Date of Electronic Publication: 2022 May 09 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , Antineoplastic Agents* , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Lymphoma, B-Cell*/drug therapy , Multiple Myeloma*, Humans ; Amyloid Precursor Protein Secretases ; B-Cell Maturation Antigen ; T-Lymphocytes

المؤلفون: Casneuf T; Janssen Research & Development, Beerse, Belgium. tcasneu1@its.jnj.com., Adams HC 3rd; Janssen Research & Development, LLC, Spring House, PA, USA., van de Donk NWCJ; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Abraham Y; Janssen Research & Development, Beerse, Belgium., Bald J; Janssen Research & Development, LLC, Spring House, PA, USA., Vanhoof G; Janssen Research & Development, Beerse, Belgium., Van der Borght K; Janssen Research & Development, Beerse, Belgium., Smets T; Janssen Research & Development, Beerse, Belgium., Foulk B; Janssen Research & Development, LLC, Spring House, PA, USA., Nielsen KC; Janssen Research & Development, LLC, Spring House, PA, USA., Rusbuldt J; Janssen Research & Development, LLC, Spring House, PA, USA., Axel A; Janssen Research & Development, LLC, Spring House, PA, USA., Lysaght A; Immuneering Corp, Cambridge, MA, USA., Ceulemans H; Janssen Research & Development, Beerse, Belgium., Stevenaert F; Janssen Research & Development, Beerse, Belgium., Usmani SZ; Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA., Plesner T; Vejle Hospital and University of Southern Denmark, Vejle, Denmark., Avet-Loiseau H; Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France., Nijhof I; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Mutis T; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Schecter JM; Janssen Research & Development, LLC, Raritan, NJ, USA., Chiu C; Janssen Research & Development, LLC, Spring House, PA, USA., Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.

المصدر: Leukemia [Leukemia] 2021 Feb; Vol. 35 (2), pp. 573-584. Date of Electronic Publication: 2020 May 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biomarkers/*analysis , Killer Cells, Natural/*immunology , Multiple Myeloma/*immunology , T-Lymphocytes/*immunology , T-Lymphocytes, Regulatory/*immunology, Antibodies, Monoclonal/administration & dosage ; Dexamethasone/administration & dosage ; Humans ; Killer Cells, Natural/drug effects ; Lenalidomide/administration & dosage ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; T-Lymphocytes/drug effects ; T-Lymphocytes, Regulatory/drug effects

المؤلفون: Frerichs KA; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Broekmans MEC; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Marin Soto JA; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., van Kessel B; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Heymans MW; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands., Holthof LC; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Verkleij CPM; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Boominathan R; Janssen Research and Development, LLC, Spring House, Pennsylvania., Vaidya B; Janssen Research and Development, LLC, Spring House, Pennsylvania., Sendecki J; Janssen Research and Development, LLC, Spring House, Pennsylvania., Axel A; Janssen Research and Development, LLC, Spring House, Pennsylvania., Gaudet F; Janssen Research and Development, LLC, Spring House, Pennsylvania., Pillarisetti K; Janssen Research and Development, LLC, Spring House, Pennsylvania., Zweegman S; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., Adams HC 3rd; Janssen Research and Development, LLC, Spring House, Pennsylvania., Mutis T; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands. n.vandedonk@amsterdamumc.nl.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 May 01; Vol. 26 (9), pp. 2203-2215. Date of Electronic Publication: 2020 Jan 22.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Bispecific/*pharmacology , Antibodies, Monoclonal/*pharmacology , B-Cell Maturation Antigen/*immunology , CD3 Complex/*immunology , Multiple Myeloma/*drug therapy, Antibodies, Bispecific/immunology ; Antibody-Dependent Cell Cytotoxicity ; Antineoplastic Agents/pharmacology ; Bone Marrow/pathology ; Drug Evaluation, Preclinical ; Drug Synergism ; Drug Therapy, Combination ; Humans ; Immunotherapy/methods ; Multiple Myeloma/immunology ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Tumor Cells, Cultured

المؤلفون: Regnante JM; 1 Sustainable Healthy Communities, Washington, DC., Richie NA; 2 Genentech, South San Francisco, CA., Fashoyin-Aje L; 3 US Food and Drug Administration, Bethesda, MD., Vichnin M; 4 Merck & Co, Kenilworth, NJ., Ford M; 5 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC., Roy UB; 6 LUNGevity Foundation, Chicago, IL., Turner K; 7 Johnson & Johnson, New Brunswick, NJ., Hall LL; 1 Sustainable Healthy Communities, Washington, DC., Gonzalez E; 8 Fox Chase Cancer Center, Philadelphia, PA., Esnaola N; 9 Houston Methodist Hospital, Houston, TX., Clark LT; 4 Merck & Co, Kenilworth, NJ., Adams HC 3rd; 10 Janssen Research & Development, Raritan, NJ., Alese OB; 11 Winship Cancer Institute of Emory University, Atlanta, GA., Gogineni K; 11 Winship Cancer Institute of Emory University, Atlanta, GA., McNeill L; 12 University of Texas MD Anderson Cancer Center, Houston, TX., Petereit D; 13 Rapid City Regional Cancer Care Institute, Rapid City, SD., Sargeant I; 14 Ismedica, Wrinehill, United Kingdom., Dang J; 15 University of California, Davis Comprehensive Cancer Center, Davis, CA., Obasaju C; 16 Eli Lilly, Indianapolis, IN., Highsmith Q; 2 Genentech, South San Francisco, CA., Lee SC; 17 University of Texas Southwestern Medical Center, Dallas, TX., Hoover SC; 18 Henry Ford Cancer Institute, Detroit, MI., Williams EL; 17 University of Texas Southwestern Medical Center, Dallas, TX., Chen MS Jr; 15 University of California, Davis Comprehensive Cancer Center, Davis, CA.

المصدر: Journal of oncology practice [J Oncol Pract] 2019 Apr; Vol. 15 (4), pp. e289-e299. Date of Electronic Publication: 2019 Mar 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101261852 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-469X (Electronic) Linking ISSN: 15547477 NLM ISO Abbreviation: J Oncol Pract Subsets: MEDLINE

مواضيع طبية MeSH: Ethnicity* , Racial Groups*, Cancer Care Facilities/*standards, Clinical Trials as Topic ; Female ; Humans ; Male ; United States

المؤلفون: Adams HC 3rd; Janssen Research & Development, LLC, Spring House, Pennsylvania., Stevenaert F; Janssen Research & Development, Beerse, Belgium., Krejcik J; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.; Department of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark., Van der Borght K; Janssen Research & Development, Beerse, Belgium., Smets T; Janssen Research & Development, Beerse, Belgium., Bald J; Janssen Research & Development, LLC, Spring House, Pennsylvania., Abraham Y; Janssen Research & Development, Beerse, Belgium., Ceulemans H; Janssen Research & Development, Beerse, Belgium., Chiu C; Janssen Research & Development, LLC, Spring House, Pennsylvania., Vanhoof G; Janssen Research & Development, Beerse, Belgium., Usmani SZ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina., Plesner T; Department of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark., Lonial S; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Nijhof I; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Lokhorst HM; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Mutis T; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., van de Donk NWCJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Sasser AK; Genmab US, Inc, Princeton, New Jersey., Casneuf T; Janssen Research & Development, Beerse, Belgium.

المصدر: Cytometry. Part A : the journal of the International Society for Analytical Cytology [Cytometry A] 2019 Mar; Vol. 95 (3), pp. 279-289. Date of Electronic Publication: 2018 Dec 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 101235694 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4930 (Electronic) Linking ISSN: 15524922 NLM ISO Abbreviation: Cytometry A Subsets: MEDLINE

مواضيع طبية MeSH: ADP-ribosyl Cyclase 1/*immunology , Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Killer Cells, Natural/*drug effects , Killer Cells, Natural/*immunology , Multiple Myeloma/*drug therapy , Multiple Myeloma/*immunology, Antigens, Differentiation, T-Lymphocyte/metabolism ; Basophils/cytology ; Basophils/drug effects ; Basophils/immunology ; Bone Marrow Cells/cytology ; Bone Marrow Cells/immunology ; CD4-Positive T-Lymphocytes/cytology ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/cytology ; CD8-Positive T-Lymphocytes/immunology ; Flow Cytometry ; Granzymes/metabolism ; Humans ; Immunophenotyping ; Killer Cells, Natural/cytology ; Multiple Myeloma/blood ; Multiple Myeloma/metabolism ; Recurrence

المؤلفون: Smets T; Janssen Research and Development, Beerse, Belgium., Stevenaert F; Janssen Research and Development, Beerse, Belgium., Adams HC 3rd; Janssen Research and Development, LLC, Spring House, PA, USA., Vanhoof G; Janssen Research and Development, Beerse, Belgium. gvhoo1@its.jnj.com.

المصدر: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2018; Vol. 1792, pp. 47-54.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 9214969 Publication Model: Print Cited Medium: Internet ISSN: 1940-6029 (Electronic) Linking ISSN: 10643745 NLM ISO Abbreviation: Methods Mol Biol Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers* , Flow Cytometry*/methods , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization*/methods, Immune System/*immunology , Immune System/*metabolism , Multiple Myeloma/*immunology , Multiple Myeloma/*metabolism, Blood Cells ; Bone Marrow Cells/immunology ; Bone Marrow Cells/metabolism ; Humans ; Immunophenotyping

المؤلفون: Casneuf T; Janssen Research & Development, Beerse, Belgium., Xu XS; Janssen Research & Development, LLC, Raritan, NJ., Adams HC 3rd; Janssen Research & Development, LLC, Spring House, PA., Axel AE; Janssen Research & Development, LLC, Spring House, PA., Chiu C; Janssen Research & Development, LLC, Spring House, PA., Khan I; Janssen Research & Development, LLC, Raritan, NJ., Ahmadi T; Janssen Research & Development, LLC, Spring House, PA., Yan X; Janssen Research & Development, LLC, Raritan, NJ., Lonial S; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Plesner T; Vejle Hospital and University of Southern Denmark, Vejle, Denmark; and., Lokhorst HM; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., van de Donk NWCJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Clemens PL; Janssen Research & Development, LLC, Spring House, PA., Sasser AK; Janssen Research & Development, LLC, Spring House, PA.

المصدر: Blood advances [Blood Adv] 2017 Oct 24; Vol. 1 (23), pp. 2105-2114. Date of Electronic Publication: 2017 Oct 24 (Print Publication: 2017).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: eCollection Cited Medium: Print ISSN: 2473-9529 (Print) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: PubMed not MEDLINE

المؤلفون: Lewis MT; Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA., Landua JD, Adams HC 3rd, Medina D

المصدر: Journal of mammary gland biology and neoplasia [J Mammary Gland Biol Neoplasia] 2012 Jun; Vol. 17 (2), pp. 99-101. Date of Electronic Publication: 2012 May 13.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 9601804 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7039 (Electronic) Linking ISSN: 10833021 NLM ISO Abbreviation: J Mammary Gland Biol Neoplasia Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological* , Morphogenesis*, Adult Stem Cells/*cytology , Adult Stem Cells/*transplantation , Biocompatible Materials/*administration & dosage , Collagen/*administration & dosage , Laminin/*administration & dosage , Mammary Glands, Animal/*cytology , Mammary Glands, Animal/*growth & development , Proteoglycans/*administration & dosage, Adult Stem Cells/metabolism ; Animals ; Biocompatible Materials/metabolism ; Cell Differentiation ; Cell Growth Processes ; Cells, Cultured ; Collagen/metabolism ; Drug Combinations ; Epithelium/metabolism ; Female ; Graft Survival ; Humans ; Laminin/metabolism ; Mammary Glands, Animal/metabolism ; Mammary Glands, Human/cytology ; Mammary Glands, Human/metabolism ; Mice ; Proteoglycans/metabolism ; Sarcoma/metabolism ; Stem Cell Niche